Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Detection of endogenously circulating Mesenchymal Stem Cells in human cancer patients.

van der Velden DL, Houthuijzen JM, Roodhart JML, van Werkhoven E, Voest EE.

Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31727. [Epub ahead of print]

PMID:
29992568
2.

Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.

van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE.

Cancer Chemother Pharmacol. 2018 May;81(5):911-921. doi: 10.1007/s00280-018-3563-2. Epub 2018 Mar 24.

PMID:
29574584
3.

Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance.

Houthuijzen JM, Oosterom I, Hudson BD, Hirasawa A, Daenen LGM, McLean CM, Hansen SVF, van Jaarsveld MTM, Peeper DS, Jafari Sadatmand S, Roodhart JML, van de Lest CHA, Ulven T, Ishihara K, Milligan G, Voest EE.

FASEB J. 2017 May;31(5):2195-2209. doi: 10.1096/fj.201601248R. Epub 2017 Feb 9.

4.

Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.

Bus P, Kestens C, Ten Kate FJ, Peters W, Drenth JP, Roodhart JM, Siersema PD, van Baal JW.

J Gastroenterol. 2016 Jun;51(6):560-70. doi: 10.1007/s00535-015-1133-5. Epub 2015 Nov 19.

5.

Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.

Daenen LG, Cirkel GA, Houthuijzen JM, Gerrits J, Oosterom I, Roodhart JM, van Tinteren H, Ishihara K, Huitema AD, Verhoeven-Duif NM, Voest EE.

JAMA Oncol. 2015 Jun;1(3):350-8. doi: 10.1001/jamaoncol.2015.0388.

PMID:
26181186
6.

Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response.

Houthuijzen JM, Daenen LG, Roodhart JM, Oosterom I, van Jaarsveld MT, Govaert KM, Smith ME, Sadatmand SJ, Rosing H, Kruse F, Helms BJ, van Rooijen N, Beijnen JH, Haribabu B, van de Lest CH, Voest EE.

Nat Commun. 2014 Nov 12;5:5275. doi: 10.1038/ncomms6275.

PMID:
25387467
7.

Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.

Gerritse FL, Meulenbeld HJ, Roodhart JM, van der Velden AM, Blaisse RJ, Smilde TJ, Erjavec Z, de Wit R, Los M; NePro Study Investigators.

Eur J Cancer. 2013 Oct;49(15):3176-83. doi: 10.1016/j.ejca.2013.06.008. Epub 2013 Jul 9.

PMID:
23849828
8.

Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance.

Roodhart JM, He H, Daenen LG, Monvoisin A, Barber CL, van Amersfoort M, Hofmann JJ, Radtke F, Lane TF, Voest EE, Iruela-Arispe ML.

Blood. 2013 Jul 4;122(1):143-53. doi: 10.1182/blood-2012-11-459347. Epub 2013 May 20.

9.

Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies.

Daenen LG, Houthuijzen JM, Cirkel GA, Roodhart JM, Shaked Y, Voest EE.

Oncogene. 2014 Mar 13;33(11):1341-7. doi: 10.1038/onc.2013.94. Epub 2013 Mar 25. Review.

PMID:
23524584
10.

Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.

Kroeze SG, Daenen LG, Nijkamp MW, Roodhart JM, de Gast GC, Bosch JL, Jans JJ.

J Urol. 2012 Aug;188(2):607-14. doi: 10.1016/j.juro.2012.03.116. Epub 2012 Jun 15.

PMID:
22704448
11.

The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression.

Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE.

Br J Cancer. 2012 Jun 5;106(12):1901-6. doi: 10.1038/bjc.2012.201. Epub 2012 May 17. Review.

12.

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.

Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE.

Eur Urol. 2012 Oct;62(4):685-95. doi: 10.1016/j.eururo.2012.01.020. Epub 2012 Jan 23.

PMID:
22285764
13.

Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells.

Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, Derksen PW, Voest EE.

Cancer Res. 2011 Nov 15;71(22):6976-85. doi: 10.1158/0008-5472.CAN-11-0627. Epub 2011 Oct 5.

14.

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.

Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE.

Cancer Cell. 2011 Sep 13;20(3):370-83. doi: 10.1016/j.ccr.2011.08.010.

15.

Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.

Schackmann RC, van Amersfoort M, Haarhuis JH, Vlug EJ, Halim VA, Roodhart JM, Vermaat JS, Voest EE, van der Groep P, van Diest PJ, Jonkers J, Derksen PW.

J Clin Invest. 2011 Aug;121(8):3176-88. doi: 10.1172/JCI41695. Epub 2011 Jul 11.

16.

Vascular disrupting agents (VDAs) in anticancer therapy.

Daenen LG, Roodhart JM, Shaked Y, Voest EE.

Curr Clin Pharmacol. 2010 Aug;5(3):178-85. Review.

PMID:
20406172
17.

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE.

Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16.

18.

Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF.

Langenberg MH, Nijkamp MW, Roodhart JM, Snoeren N, Tang T, Shaked Y, van Hillegersberg R, Witteveen PO, Vermaat JS, Kranenburg O, Kerbel RS, Medema RH, Borel Rinkes IH, Voest EE.

Cancer Biol Ther. 2010 May 1;9(9):743-8. Epub 2010 May 18.

PMID:
20215863
19.

Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.

Langenberg MH, Witteveen PO, Lankheet NA, Roodhart JM, Rosing H, van den Heuvel IJ, Beijnen JH, Voest EE.

Neoplasia. 2010 Feb;12(2):206-13.

20.

Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients.

Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, Voest EE.

Neoplasia. 2010 Jan;12(1):87-94.

21.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE.

Ann Oncol. 2010 Jul;21(7):1472-81. doi: 10.1093/annonc/mdp559. Epub 2009 Dec 18.

PMID:
20022911
22.

Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back.

Roodhart JM, Langenberg MH, Daenen LG, Voest EE.

Biochim Biophys Acta. 2009 Aug;1796(1):41-9. doi: 10.1016/j.bbcan.2009.04.006. Epub 2009 May 4. Review.

PMID:
19409450
23.

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS.

Cancer Cell. 2008 Sep 9;14(3):263-73. doi: 10.1016/j.ccr.2008.08.001.

24.

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.

Roodhart JM, Langenberg MH, Witteveen E, Voest EE.

Curr Clin Pharmacol. 2008 May;3(2):132-43. Review.

PMID:
18690886
25.

Supplemental Content

Loading ...
Support Center